TrialCPT: pharmacometrics & systems pharmacology2017

Simultaneous Modeling of Biomarker and Toxicity Response Predicted Optimal Regimen of Guadecitabine (SGI-110) in Myeloid Malignancies.

Cong Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.